[
  {
    "ts": null,
    "headline": "Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time",
    "summary": "Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.",
    "url": "https://finnhub.io/api/news?id=df78ec9188ca4da804ec1313c3d94767caaabe52f9a2476c20ff44da47da015c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754229600,
      "headline": "Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time",
      "id": 136192173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.",
      "url": "https://finnhub.io/api/news?id=df78ec9188ca4da804ec1313c3d94767caaabe52f9a2476c20ff44da47da015c"
    }
  },
  {
    "ts": null,
    "headline": "This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?",
    "summary": "Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.",
    "url": "https://finnhub.io/api/news?id=17c7868615f5d8ed13cb17a0f36c13fb88b4eb60a0f6daf6752c3d0f669642c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754226002,
      "headline": "This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?",
      "id": 136195511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.",
      "url": "https://finnhub.io/api/news?id=17c7868615f5d8ed13cb17a0f36c13fb88b4eb60a0f6daf6752c3d0f669642c6"
    }
  },
  {
    "ts": null,
    "headline": "The one-year underlying earnings growth at Merck (NYSE:MRK) is promising, but the shareholders are still in the red over that time",
    "summary": "Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...",
    "url": "https://finnhub.io/api/news?id=7f049283462e1b836d277604ae0a76d6a8f4a422b73311f56d33db78671b902a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754222428,
      "headline": "The one-year underlying earnings growth at Merck (NYSE:MRK) is promising, but the shareholders are still in the red over that time",
      "id": 136195512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...",
      "url": "https://finnhub.io/api/news?id=7f049283462e1b836d277604ae0a76d6a8f4a422b73311f56d33db78671b902a"
    }
  }
]